Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Annovis Bio Inc

Healthcare US ANVS

1.73USD
-0.04(2.26%)

Last update at 2026-06-23T20:00:00Z

Day Range

1.711.79
LowHigh

52 Week Range

1.365.50
LowHigh

Fundamentals

  • Previous Close 1.77
  • Market Cap64.23M
  • Volume655336
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -28.85420M -24.59038M -56.20400M -25.32857M -14.48713M
Minority interest - - - - -
Net income -28.85420M -24.59038M -56.20400M -25.14586M -14.43704M
Selling general administrative 4479.65M 6.70M 6.24M 9.00M 6.06M
Selling and marketing expenses - 0.10M 0.10M - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - - -45.03501M - -14.53722M
Ebitda -29.69526M -26.69493M -45.03500M -25.51128M -14.50047M
Depreciation and amortization - - 0.00000M - 0.04M
Non operating income net other - - - - 0.04M
Operating income -29.69526M -26.69493M -45.03500M -25.51128M -14.53722M
Other operating expenses 29.70M 26.69M 45.03M 25.51M 14.50M
Interest expense - 1.85M - -0.18271M 0.01M
Tax provision - - - - -
Interest income 0.70M 0.33M 0.68M 0.18M 0.01M
Net interest income 0.70M -1.52134M 0.68M 0.18M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -24565.78500M -0.04503M -0.18271M -0.05009M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 29.70M 26.69M 45.03M 25.51M 14.50M
Cost of revenue - - - - -
Total other income expense net 0.84M 2.10M -11.16900M 0.18M 0.05M
Discontinued operations - - - - -
Net income from continuing ops -28.85420M -24.59038M -41.71709M -25.32857M -14.48713M
Net income applicable to common shares - - - - -14.48713M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.08M 13.93M 10.21M 36.02M 46.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets -19511.25638M 3.37M 4.45M 7644.38M 315.46M
Total liab 4.23M 4.62M 17.96M 7.70M 1.51M
Total stockholder equity 16.85M 9.31M -7.75085M 28.32M 44.49M
Deferred long term liab - - - - -
Other current liab 1.04M 1.58M 2.99M 3.74M 0.82M
Common stock 0.00272M 0.00141M 0.00105M 0.00082M 0.00081M
Capital stock 0.00272M 0.00141M 0.00105M 0.00082M 0.00081M
Retained earnings -163.70366M -134.84946M -110.25909M -54.05477M -28.72621M
Other liab - - - - -
Good will - - - - -
Other assets 1549.29M 3373.72M - - -
Cash 19532.34M 10.55M 5.75M 28.38M 45.69M
Cash and equivalents - - - - -
Total current liabilities 3.64M 3.88M 4.28M 7.70M 1.51M
Current deferred revenue - - - - -
Net debt -19532.33800M -10.55192M -5.75472M -28.37769M -45.68601M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 180.55M 144.16M 102.51M 82.38M 73.22M
Property plant equipment - - - - -
Total current assets 21.08M 13.93M 10.21M 36.02M 46.00M
Long term investments - - - - -
Net tangible assets - - - - 44.49M
Short term investments - 10541.36M - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.59M 2.31M 1.29M 3.96M 0.69M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00081M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -28.72621M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1549.29M - - - -
Deferred long term asset charges - - - - -
Non current assets total 1549.29M 13911.71M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -
Change to liabilities - - - - 0.93M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 34600.12M 26691.80M 17.34M 0.00461M 46.74M
Change to operating activities - - - - 0.31M
Net income -28854.19700M -24590.37500M -56.20431M -25.32857M -14.48713M
Change in cash 8980.42M 4797.20M -22.62297M -17.30832M 37.61M
Begin period cash flow 10551.92M 5754.72M 28.38M 45.69M 8.07M
End period cash flow 19532.34M 10551.92M 5.75M 28.38M 45.69M
Total cash from operating activities -25619.70300M -21894.60400M -39.96730M -17.31293M -9.13216M
Issuance of capital stock 34.60M 18.67M 8.57M 0.00000M 46.65M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - 46.74M
Other cashflows from financing activities 34565.52M 26673.13M 0.46M 0.00461M 0.10M
Change to netincome - - - - 4.70M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -0.27079M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 37.61M
Change in working capital 1.58M 0.68M -0.22860M -1.13689M 0.66M
Stock based compensation 1797.68M 3836.77M 4.63M 9.15M 4.70M
Other non cash items 1435.24M -1141.68070M 11.84M - 14472.64M
Free cash flow -25619.70300M -21894.60400M -39.96730M -17.31293M -9.13216M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ANVS
Annovis Bio Inc		 -0.04 2.26% 1.73 - - - 3.94 -3.5651
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Annovis Bio Inc

101 Lindenwood Drive, Malvern, PA, United States, 19355

Key Executives

Name Title Year Born
Dr. Maria L. Maccecchini Ph.D. Founder, CEO, Pres & Exec. Director 1951
Mr. Henry Hagopian III, M.B.A. Chief Financial Officer 1968
Dr. Cheng Fang Ph.D. Sr. VP of R&D NA
Ms. Eve M. Damiano M.S., RAC Sr. VP of Regulatory Operations NA
Dr. Maria L. Maccecchini Ph.D. Founder, Acting CFO, CEO, President & Executive Director 1951
Dr. Cheng Fang Ph.D. Senior Vice President of Research & Development NA
Ms. Eve M. Damiano M.S., RAC Senior Vice President of Regulatory Operations NA
Mr. Blake Jensen M.B.A. Head of Quality NA
Ms. Hilda Maibach Senior Vice President of Statistics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.